FY2025 Earnings Estimate for SXTP Issued By HC Wainwright

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) – HC Wainwright dropped their FY2025 earnings per share estimates for shares of 60 Degrees Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 27th. HC Wainwright analyst M. Keller now forecasts that the company will post earnings of ($13.63) per share for the year, down from their prior estimate of ($13.56). HC Wainwright currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for 60 Degrees Pharmaceuticals’ current full-year earnings is ($5.09) per share.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last released its earnings results on Thursday, November 13th. The company reported ($2.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.84) by $2.20. The firm had revenue of ($0.01) million for the quarter, compared to analyst estimates of $0.38 million.

Several other research analysts have also issued reports on SXTP. Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Monday, December 29th. Zacks Research upgraded 60 Degrees Pharmaceuticals to a “hold” rating in a research report on Tuesday, November 18th. Finally, Ascendiant Capital Markets reduced their target price on 60 Degrees Pharmaceuticals from $12.00 to $11.20 and set a “buy” rating for the company in a report on Friday, November 28th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $17.60.

60 Degrees Pharmaceuticals Trading Down 14.3%

NASDAQ:SXTP opened at $4.15 on Thursday. The company has a 50-day moving average of $3.23 and a 200-day moving average of $4.71. The firm has a market cap of $4.40 million, a price-to-earnings ratio of -0.30 and a beta of 2.98. 60 Degrees Pharmaceuticals has a twelve month low of $1.36 and a twelve month high of $17.68.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.